TapImmune to Present at the 2017 BioFlorida Conference

JACKSONVILLE, Fla., Oct. 12, 2017 /PRNewswire/ -- TapImmune Inc. (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced that representatives of the Company will be featured in two panel discussions at the 2017 BioFlorida Conference, held October 15-17, at The Vinoy Renaissance St. Petersburg Resort and Golf Club. The Company will be featured in the BioBusiness Session on Monday, October 16^th, and in the BioTrends Session on Tuesday, October 17^th, and will participate in one-on-one meetings with potential strategic collaboration partners.

About TapImmune Inc.
TapImmune Inc. is a leader in the development of novel immunotherapies for cancer.  The Company is a leader in the development of immunotherapies for women's cancers, with multiple Phase 2 and Phase 1b/2 clinical studies for the treatment of ovarian and breast cancer. The company's peptide- or nucleic acid-based immunotherapeutic products comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient's killer T cells and helper T cells, and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The company's technologies may be used as stand-alone medications or in combination with current treatment modalities.

About BioFlorida
BioFlorida is the voice of Florida's life sciences industry, representing nearly 6,000 establishments and research organizations in the biopharmaceutical, medical technology and bioagriculture sectors that collectively employ nearly 83,000 Floridians.

For additional information, please call (904) 862-6490 EXT. 102 or visit: https://tapimmune.com/

To receive future press releases via email, please visit:
https://tapimmune.com/investors/email-alerts/

Follow us on Twitter @Tapimmune_Inc, or follow us on Facebook.

For answers to frequently asked questions, please visit our FAQs page: https://tapimmune.com/investors/frequently-asked-questions/

Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements." Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the results of the Phase II clinical trials, the ability to obtain regulatory approval of TPIV 200, the Company's ability to raise future financing for continued development and the ability to successfully commercialize TPIV 200 as well as the risks and uncertainties set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.

View original content with multimedia:http://www.prnewswire.com/news-releases/tapimmune-to-present-at-the-2017-bioflorida-conference-300535062.html

SOURCE TapImmune Inc.